Tysabri (natalizumab) - Biogen, Royalty
Digital signatures of fatigue and wearing-off symptoms in patients with multiple sclerosis under natalizumab. (PubMed, Neurotherapeutics) - Sep 19, 2026 - P | "These exploratory findings indicate that, in this clinically stable cohort, WoS under NTZ do not reflect ongoing inflammatory or neurodegenerative disease activity, but rather align with fatigue-related motor changes detectable by high-adherence passive wearables. Dynamic wearable activity metrics warrant evaluation as digital endpoints for fatigue-focused interventions and clinical care." 
Journal • CNS Disorders • Fatigue • Multiple Sclerosis • GFAP • NEFL • VCAM1
http://www.ncbi.nlm.nih.gov/pubmed/42759177
 
Elaine Trautmann; Jan Voth; Jens Kuhle; Judith von Pavel; Jörn Kaufmann; Lars Masanneck; Marc Pawlitzki; Marie Deffner; Marius Vach; Melanie Schuette; Nicholas Schwab; Pascal Benkert; Patricia Kirschner; Ramona Hagler; Steffen Pfeuffer; Sven G Meuth
 
Sep 19, 2026
 
Prev Next